Skip to content

#自身免疫

Today 0 items
Oct 13Tue
  1. biopharmadive.com40

    Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data

    Bausch + Lomb named board chair Thomas Appio interim CEO after he and Brent Saunders mutually agreed to Saunders' exit, and raised its 2026 earnings outlook. Merck disclosed that proliferative diabetic retinopathy adverse events occurred in 6.7% and 6.1% of remigromig patients versus 0.9% on Lucentis, with the drug not superior on secondary measures. Amgen and AstraZeneca reported nearly 70% of eosinophilic esophagitis patients on Tezspire's highest dose were in remission at 24 weeks; the FDA also approved Asahi Kasei's Hovilpri.

    Why it matters: CEO change at Bausch + Lomb plus pivotal safety and efficacy data on remigromig, Tezspire and a new HSV approval.

Oct 9Fri
  1. biospace.com80

    How Abogen went from COVID hype to a $7.8B Novartis deal

    Novartis has taken an exclusive worldwide license to ABO2203, Abogen Biosciences' mRNA-encoded CD19xCD3 T cell engager for B-cell malignancies and autoimmune diseases, paying $575 million upfront with up to roughly $7.2 billion in potential option, milestone and royalty payments. Early data in relapsed or refractory B-cell non-Hodgkin lymphoma showed overall response rates of 33%, 67% and 100% across dose cohorts, with no CRS or ICANS reported. The deal, which also gives Novartis options on further Abogen RNA platform programs, marks Abogen's shift beyond its faded COVID vaccine business.

    Why it matters: Large upfront payment signals big-pharma validation of in vivo mRNA T cell engagers and Abogen's post-COVID pivot.

  2. biopharmadive.com61

    TRex Bio prices $117M IPO to support immune drug work

    TRex Bio priced a $117 million IPO, selling 8,333,334 shares at $14 each, and begins trading Friday on Nasdaq under "TRXB." The company is developing Treg-activating drugs for immunological conditions, including TRB-061, in a Phase 1 trial with topline data expected in 2027, and TRB-071 for inflammatory bowel disease, which could enter testing next year. Eli Lilly, TRex's largest equity holder at about 24% pre-IPO, and Johnson & Johnson have licensed or optioned treatments discovered by TRex, which has raised $220 million in venture financing to date.

    Why it matters: IPO shows continued investor appetite for immune-focused biotechs, with six of 23 drug developers going public in 2026 working on immune diseases.

Oct 8Thu
  1. biospace.com66

    Big Pharma–backed Matchpoint scores $150M series B, advancing autoimmune asset

    Preclinical Matchpoint Therapeutics has raised a $150 million series B co-led by Nextech Invest and Norwest, with participation from Sanofi Ventures, Atlas Venture, Access Biotechnology and the T1D Fund. The money will advance MPT-062, an oral T cell modulator for autoimmune and inflammatory conditions, into human trials starting next year. Matchpoint also has a July 2025 deal with Novartis, which paid $60 million upfront for its ACE platform and could owe up to $1 billion in milestones plus royalties.

    Why it matters: A large series B funds a first-in-class oral autoimmune program before it reaches human trials, against a market trend favouring later-stage assets.

Oct 5Mon
  1. biospace.com62

    CSL strikes up to $1.6B deal with Alentis for autoimmune drug with broad potential

    CSL will pay Alentis Therapeutics $355 million upfront, with up to $1.2 billion more, to co-develop and co-promote the claudin-1-targeting antibody lixudebart. The drug is in the Phase 2 RENAL trial for AAV-RPGN, a rare autoimmune kidney disease, and is also planned for mid-stage development in FSGS and PSC, with CSL funding these studies and any approved product profits split 55/45 in CSL's favour. An FDA orphan drug designation for IPF, granted in May 2024, sits outside the deal.

Oct 3Sat
  1. biocentury.com67

    Novartis turns to mRNA-encoded engagers for B cell depletion

    Novartis is paying Suzhou Abogen Biosciences $575 million up front for exclusive worldwide rights to ABO2203, an mRNA-encoded CD19 x CD3 T cell engager for autoimmune indications, plus options on undisclosed next-generation assets from Abogen's RNA platform. Abogen could receive up to $7.2 billion in milestones if all options are exercised. Early clinical data support the mRNA-encoded T cell engager approach, which adds a new modality to B cell-depleting therapies for autoimmune diseases.

Oct 2Fri
  1. biopharmadive.com65

    Sanofi, Regeneron broaden alliance to find their next Dupixent

    Sanofi and Regeneron have expanded their alliance to co-develop and co-commercialize four long-acting, Regeneron-invented antibodies targeting IL-13, IL-4 or an IL-4 subunit, like Dupixent. The most advanced, REGN20423, is in an early-stage eczema trial; the other three should enter human testing next year. Regeneron receives $1 billion up front and as much as $7 billion in milestone payments, and can opt to add Sanofi's lunsekimig after certain late-stage studies. Dupixent, first cleared in 2017, brought in $10.9 billion in net sales in the first half of this year.

    Why it matters: Expanded Sanofi-Regeneron alliance with $1 billion up front and up to $7 billion in milestones aims to extend the Dupixent franchise.

Oct 1Thu
  2. statnews.com60

    STAT+: Sanofi, Regeneron expand partnership after Dupixent success

    Sanofi and Regeneron Pharmaceuticals, partners on Dupixent, have expanded their collaboration to develop a new series of antibodies for immunological diseases. Sanofi will pay Regeneron $1 billion upfront, with possible milestone payments of up to $7 billion more. Regeneron will lead research and development, Sanofi will lead commercialization, and profits will be split evenly.

Sep 1Tue
  1. biocentury.com55

    Lilly’s deal spree continues with Merida takeout: Deals Report

    Eli Lilly has agreed to acquire Merida Biosciences, a four-year-old Cambridge, Massachusetts autoimmunity and allergy biotech, in a deal valued at up to $2.88 billion. The acquisition gives Lilly MER511, a Phase I Fc therapeutic that binds anti-TSHR autoantibodies for Graves' disease and thyroid eye disease. Merida raised a $121 million series A in 2025 co-led by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures.

    Why it matters: Lilly's thirteenth takeout expands its autoimmune pipeline into Graves' disease and thyroid eye disease.

Aug 20Thu
  1. fiercepharma.com47

    Aurinia settles with Teva, helping stave off potential Lupkynis generic until late 2036

    Aurinia Pharmaceuticals has settled a patent infringement suit with Teva Pharmaceuticals, keeping Teva's proposed generic of the lupus drug Lupkynis (voclosporin) off the U.S. market until December 2036, unless certain defined contingencies occur earlier. The settlement assumes Teva wins FDA approval of its version. Aurinia still faces patent litigation with DifGen, Dr. Reddy's, Hikma, Sandoz and Zydus in U.S. District Court in New Jersey.

Aug 18Tue
  1. fiercepharma.com58

    CSL shares up 17% as immunoglobulin boost points to signs of recovery

    CSL shares rose more than 17% after the Australian plasma and vaccine specialist reported fiscal 2026 sales of $15.8 billion and projected mid-single-digit growth for its CSL Behring unit in FY27. Immunoglobulin demand increased 7% year over year, and the HAE drug Andembry brought in $240 million. Vifor Pharma sales are projected to decline 25% in FY27 after $7.1 billion in impairments.

  2. fiercepharma.com54

    Sanofi to lay off 229 Blueprint Medicines staffers, close Cambridge offices following acquisition

    Sanofi is laying off 229 Blueprint Medicines employees in Massachusetts and closing two legacy Blueprint sites in Cambridge, including the former global headquarters at 45 Sidney St. The cuts, detailed in a WARN notice, follow Sanofi's $9.1 billion acquisition of Blueprint, which brought the rare immunology drug Ayvakit and KIT inhibitor candidates. Layoffs will occur between October 2026 and June 2027, and remaining Blueprint staff will move to Sanofi's Cambridge Crossing campus.

Aug 15Sat
  1. BioCentury47

    Boulevard: Homing in on B cell biology in autoimmunity

    Deerfield-incubated Boulevard Bio launched with $65 million in aggregate funding to develop B cell-directed therapies for IgA nephropathy and other autoimmune diseases. Its assets include a Phase I long-acting APRIL x BAFF bispecific for IgA nephropathy plus two preclinical autoimmune therapies. Scientific co-founders are CAR T researcher Georg Schett and former Sanofi CSO Frank Nestle.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org